Skip to main content
Premium Trial:

Request an Annual Quote

Biognosys Licenses ETH Zurich Patent for Glycoprotein Enrichment

Premium

NEW YORK (GenomeWeb) – Proteomics firm Biognosys said this week that it has licensed a patent from the Swiss Federal Institute of Technology Zurich covering a technology for capture of N-glycans.

The company said that it plans to use the technology to offer glycol-protein profiling as part of its high-resolution mass spec-based targeted quantitation offerings.

Developed by ETH Zurich research Ruedi Aebersold and colleagues at the Institute for Systems Biology in Seattle, the technique enables enrichment of N-glycosylated proteins.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.